Core Viewpoint - The article emphasizes the trend of "medical-research co-creation" in the domestic beauty industry, highlighting that while this concept is gaining traction, it is still in its infancy in China, lacking clear implementation standards. The German skincare brand Eucerin has set a precedent with its comprehensive approach to medical-research co-creation over its 125-year history [3][6]. Group 1: Eucerin's Achievements - Eucerin showcased its advancements at the 34th European Academy of Dermatology and Venereology (EADV) with three thematic satellite sessions and 18 academic posters, particularly highlighting the publication of the "International Consensus on Pigment Management," which includes the patented ingredient Thiamidol® in global treatment recommendations [4][24]. - Eucerin's practice serves as a practical guide for the Chinese beauty industry, demonstrating a successful model of medical-research co-creation [6][21]. - The brand has built a robust medical-research co-creation system, which is recognized as a competitive advantage, rooted in its unique scientific brand heritage established in 1900 [7][11]. Group 2: Research and Development - Eucerin has established a standard medical-research co-creation pathway consisting of clinical insights, product development, and efficacy evaluation, successfully navigating these core stages [12][16]. - The brand collaborates closely with thousands of dermatology experts globally and holds over 1,500 effective patents, investing more than €200 million annually in research and development [16][38]. - The efficacy of Thiamidol® has been validated through over 120 clinical studies involving more than 9,000 participants across 28 countries, proving its effectiveness for all skin types [16][29]. Group 3: Localization in China - Eucerin has effectively localized its medical-research co-creation model in China, launching the second-generation Eucerin Brightening Essence with dual certifications for "whitening" and "new ingredient registration" [19][40]. - The product development involved extensive collaboration with local dermatologists and consumer research, addressing the specific needs of Chinese consumers [19][42]. - Eucerin's innovative "Red-Brown-Black" pigment management strategy systematically addresses pigmentation issues, showcasing its commitment to localized solutions [19][21]. Group 4: Market Performance - The functional skincare market in China is rapidly growing, with the market size increasing from ¥7.42 billion in 2016 to ¥48 billion in 2024, indicating a competitive landscape [37]. - Eucerin achieved a remarkable 61.9% organic sales growth in the Chinese market in the first half of the year, significantly outperforming expectations [38][39]. - The brand's success is attributed to its comprehensive strategy, including expanding its target audience, localized R&D, entering the medical aesthetics sector, and enhancing brand communication [38][40][42]. Group 5: Academic Contributions - Eucerin's participation in the EADV conference included the release of the "International Consensus on Pigment Management," which provides a unified standard for diagnosing and treating common pigmentary disorders [27][30]. - The brand's focus on skin microbiome and anti-aging breakthroughs was highlighted in discussions led by global experts, emphasizing the importance of integrating skin science with clinical practice [30][31]. - Eucerin's product matrix, particularly its anti-pigment series, received significant attention, showcasing its commitment to evidence-based solutions in clinical and daily skincare [32][35]. Group 6: Future Outlook - Eucerin's trajectory from a German pharmacy to a prominent player on the international academic stage exemplifies the successful implementation of medical-research co-creation in the beauty industry [44]. - The brand's long-term commitment to research and development, combined with its strategic focus on the Chinese market, positions it to lead industry trends and innovations [44].

Core Viewpoint - The Chinese cosmetics market is transitioning from high-speed growth to a "new normal" of high-quality development, presenting challenges for companies like Betaini, which must demonstrate strategic resilience and future potential amid a more competitive landscape [1] Financial Performance - In the first half of 2025, Betaini reported revenue of 2.372 billion yuan and a net profit attributable to shareholders of 247 million yuan, with a non-recurring net profit of 183 million yuan, indicating pressure on revenue and profitability due to a challenging consumption environment and strategic adjustments [1][5] - The overall gross margin for the company was 76.0%, an increase of 3.4 percentage points year-on-year, while the net profit margin was 10.4%, a decrease of 6.8 percentage points year-on-year, reflecting the impact of product structure optimization and promotional strategy adjustments [5] Product and Category Analysis - Skincare products generated revenue of 2.001 billion yuan, makeup products 239 million yuan, and medical devices 116 million yuan, with the main brand Winona accounting for 82.2% of total revenue [3] - Betaini focuses on developing products for sensitive skin, covering various areas such as soothing, sun protection, whitening, anti-aging, and acne treatment, with new product launches reinforcing its technological backing [3][9] Channel Strategy - Online channel revenue was 1.743 billion yuan, with a year-on-year decline of only 5.9%, indicating strong operational resilience, while offline distribution revenue was 424 million yuan [3][12] - The company is shifting its channel strategy from broad traffic acquisition to deep user engagement, enhancing its online operations through refined membership systems and private domain traffic management [12] Market Trends and Consumer Behavior - The cosmetics industry is experiencing stricter regulations and a shift towards high-quality development, with changing consumer behaviors emphasizing ingredient transparency, rational consumption, and confidence in domestic brands [7][8] - Betaini's "1+N" brand strategy is under scrutiny, as the growth of its main brand Winona and the speed of new brand incubation will determine the company's future potential [8][9] Research and Development - The company continues to invest in research on active ingredients from Yunnan's unique plants, enhancing extraction processes and foundational research to build barriers around these ingredients [11] - Collaborations with dermatology hospitals are expanding, providing robust clinical data support for new product launches, which strengthens the efficacy and safety claims of its products [11]

Core Viewpoint - The article discusses the transformation of the Chinese cosmetics industry from "incremental competition" to "stock game," emphasizing the need for scientific validation and trust in brands as consumer expectations evolve from mere functionality to a demand for verifiable scientific evidence [5][30]. Group 1: Industry Challenges - The cosmetics industry faces multiple pain points, including insufficient time for brand establishment, lack of scientific narratives, and broken evidence chains, pushing brands to the edge [3]. - Consumers are increasingly demanding scientifically backed products, leading to a shift from marketing-driven to research-driven approaches in the industry [5]. - The absence of a unified scientific language among brands has resulted in trust confusion, making it difficult for consumers to compare product values and leading to choice anxiety [6]. Group 2: SIA100 System Introduction - The SIA100 scientific skincare evaluation system was launched to address these challenges, serving as a trust infrastructure that integrates contributions from doctors, researchers, and brands, creating a replicable industry standard [4][7]. - SIA100 is not merely a certification tool but a comprehensive framework that connects academia, research, and clinical practice, providing a unified value measurement standard for the industry [7][8]. Group 3: Expert Collaboration and Evaluation - The SIA100 system is backed by a consortium of over 200 international experts, ensuring the scientific credibility and authority of the evaluation process [8][9]. - The SIA100 evaluation criteria are dynamic and evolve annually based on the latest scientific advancements and industry needs, ensuring relevance and applicability [9]. Group 4: Industry Impact and Future Directions - The SIA100 system has already validated 42 products and 16 technologies in its first collection, demonstrating its effectiveness in bridging the gap between research and market needs [10][12]. - The SIA Alliance has gathered over 80 member companies, forming a collaborative network that enhances the ecological value of the SIA100 system and shifts scientific evaluation from a single standard to an industry consensus [12][30]. - As the demand for scientific innovation deepens, the SIA100 system will continue to evolve, expanding its categories and enhancing its evaluation dimensions by 2025 [16][30].

Core Insights - Shanghai Jahwa is undergoing a significant transformation under the leadership of CEO Lin Xiaohai, shifting from a channel-driven model to a brand-driven approach [1][2][6] - The company reported a revenue of 3.478 billion yuan in the first half of 2025, marking a 4.75% year-on-year increase, and a net profit of 266 million yuan, up 11.66% [1] Organizational Changes - The core principle of the transformation is to dismantle the old channel-centric structure and establish a vertical system where brands operate as independent units [2] - Lin Xiaohai emphasized the importance of having a management team that understands the new strategy, which was formed through informal discussions in various settings [2][6] - The new organizational design has made the company more agile, allowing each brand to thrive independently [2][6] Product Innovation - Product innovation is a key focus, with the launch of the "Mosquito Repellent Egg" by the brand Six God, which caters to modern consumer needs and outdoor scenarios [3][4] - The new product design reflects a deep understanding of consumer behavior and market trends, despite having a similar profit margin to traditional products [3][4] - The company aims to create a matrix of billion-yuan products, with a target of three such products this year and ten next year [4][5] Research and Development - Lin Xiaohai is prioritizing R&D to ensure sustainable competitive advantages for the brands [4][5] - The company is increasing the number of co-created products with medical research institutions and is working on establishing industry standards [5] - Initiatives like the "Youth Training Camp" and the "Homecoming Plan" are being implemented to attract top talent and experienced professionals back to the company [5]

Core Viewpoint - Shanghai Jahwa has demonstrated significant improvement in its financial performance, with a notable revenue increase in the second quarter, reflecting the effectiveness of its ongoing reform strategies [5][20]. Financial Performance - In the first half of 2025, Shanghai Jahwa achieved a revenue of 3.48 billion yuan, representing a year-on-year growth of 4.8% [5]. - The net profit for the same period was 270 million yuan, showing an increase of 11.7% [5]. - The second quarter alone saw a remarkable revenue growth of 25.4%, with beauty product sales increasing by 55.7% across all channels [5]. - Online sales across all brands in China recorded a 34.6% year-on-year growth [5]. - Accounts receivable decreased by 25.7%, and inventory reduced by 20.6%, while operating cash flow rose by 39.7% year-on-year [5]. Strategic Focus - The company has implemented a "four focus" strategy, which includes enhancing organizational capabilities, brand building, channel optimization, and operational quality improvement [5][20]. Product Innovation - Shanghai Jahwa has successfully launched several star products, including an upgraded portable mosquito repellent from the Liushen brand, which topped the Tmall sales chart [7]. - The new "Qinghao" cream series from the maternal and infant brand Qichu has gained significant market traction, achieving double-digit growth despite industry challenges [13]. - The Baicaoji brand has revitalized its product line with the "New Seven White" series, leading to over 50% growth in the second quarter [11]. Brand Marketing and Channel Optimization - The company has made significant strides in brand marketing, with Liushen launching a Pokémon collaboration to attract younger consumers, resulting in over 30% sales growth during the 618 shopping festival [17]. - The high-end brand Shuangmei has successfully positioned itself in the premium market, achieving top sales in the high-end essence oil category during the 618 event [15][18]. - The company has enhanced its online presence through effective collaborations with influencers and targeted marketing strategies, leading to substantial increases in brand visibility and sales [18]. Future Outlook - Looking ahead, Shanghai Jahwa has clear plans to maintain its growth momentum, focusing on product innovation and market trend alignment to solidify its position as a leading domestic brand [20].

2025年上半年，上海家化精选优势品类、重点培育战略新品、深化品牌重塑与创新。六神、玉泽两大核 心品牌线上领涨，佰草集强势复苏，高夫、启初、双妹等品牌通过新品切入细分市场。 上海家化（600315）8月21日晚间发布2025年半年度业绩报告，公司上半年实现营业收入34.8亿元，同 比增长4.8%；实现净利润2.7亿元，同比增长11.7%。 具体来看，六神品牌聚焦"专业驱蚊科技"与"年轻化形象重塑"战略，推出全新升级版便携式六神驱蚊 蛋，登顶天猫驱蚊水热销榜TOP1。玉泽品牌上半年收入实现两位数增长，召开皮肤屏障专业峰会，联 合医学专家深化"医研共创"模式，发表8篇专业医学临床论文。佰草集品牌上半年收入同比增长50%以 上，打造的大单品"佰草集大白泥"在618期间占据抖音美白、祛斑、透亮面膜榜单首位长达11天。 上海家化半年报显示，第二季度公司业绩表现亮眼，收入同比大幅增长25.4%，其中美妆品类全渠道收 入同比增长55.7%、国内全品牌线上渠道收入同比增长34.6%。上半年，公司改革成效加速释放，二季 度着力提升核心品牌价值，同步推进线上能力建设与线下渠道优化，驱动营收与利润同步提升。 在实现增长的同时，上海 ...

Core Insights - Scientific communication has become a key element for brand development in the beauty industry, as consumer demand for skincare knowledge and product efficacy continues to grow [1] - The current state of scientific communication among beauty brands is inconsistent, with many brands struggling to effectively convey their scientific narratives, leading to a lack of innovation and reduced conversion efficiency [1] Group 1: Brand Positioning and Market Recognition - Zhenyan has established itself as a leading brand in the field of dermatological skincare since its inception in 2015, focusing on skin barrier repair [2] - The brand's unique approach is characterized by a strong medical research background, with the founding team having nearly 30 years of experience in the pharmaceutical industry, which informs their rigorous product development process [2] - Zhenyan ranked in the top three choices of dermatologists for clinical skincare products, highlighting its professional standing and market recognition [4] Group 2: Product Development and Scientific Rigor - Zhenyan employs a biopharmaceutical research mindset in its product development, adhering to strict pharmaceutical-grade standards throughout the entire process, from ingredient selection to efficacy validation [2][12] - The brand has developed a unique three-force model for skin barrier repair, integrating various high-quality protein components to provide comprehensive skin barrier restoration [28] - Zhenyan's core ingredient, recombined mussel adhesive protein, has shown significant clinical efficacy in repairing damaged skin barriers and alleviating sensitivity and redness, supported by numerous academic publications [30][34] Group 3: Collaboration and Academic Engagement - Zhenyan actively collaborates with hospitals and academic institutions to enhance its product offerings and ensure they meet clinical needs, thereby creating a complete loop of medical research and innovation [10][12] - The brand has participated in various national and regional dermatology conferences to share academic findings and promote industry development [10] - Zhenyan has launched several scientific publications and guidelines in collaboration with dermatologists, further solidifying its authority in post-aesthetic care [24] Group 4: Consumer Engagement and Education - Zhenyan has initiated various consumer engagement activities, including skin health consultations and educational campaigns, to promote its skincare philosophy and enhance consumer understanding of skincare [27] - The brand has developed its own scientific communication IPs to disseminate skincare knowledge through various media formats, making professional skincare concepts more accessible to consumers [27]

Core Viewpoint - The beauty industry is increasingly entering the medical aesthetics channel, with over 20 beauty brands adopting a dual beauty strategy of "medical aesthetics + beauty" to enhance their market presence and professional credibility [2][6][30]. Group 1: Market Overview - The medical aesthetics market in China is experiencing strong growth, with 18,584 compliant specialized medical aesthetics institutions reported as of January 2024 [6][7]. - The main active regions for medical aesthetics consumption are concentrated in the Pearl River Delta, Yangtze River Delta, and Chengdu-Chongqing areas [7][8]. Group 2: Industry Structure - Medical aesthetics institutions can be categorized into three types: public hospitals, large chain private hospitals, and small private hospitals and clinics [4][5]. - The development of the domestic medical aesthetics industry has gone through three main stages: initiation (1994-2000), gradual standardization (2000-2010), and rapid development (2010-present) [5]. Group 3: Brand Strategies - Many beauty companies have established significant medical aesthetics channel layouts, such as Huaxi Biological covering 7,000 medical institutions and Juzhi Biological entering approximately 1,700 public hospitals and 3,000 private hospitals and clinics [8][10]. - International beauty brands are also accelerating their medical aesthetics channel expansion, with brands like SkinCeuticals and Estée Lauder entering high-end medical aesthetics lines [10][12]. Group 4: Consumer Trends - There is a growing consumer demand for effective skincare solutions that combine beauty products with medical treatments, reflecting a trend towards the integration of lifestyle beauty and medical aesthetics [17][20]. - Consumers are increasingly seeking products with professional medical backing and comprehensive management solutions from pre-operative care to post-operative recovery [18][20]. Group 5: Challenges and Opportunities - Despite the initial success of some brands in the medical aesthetics channel, challenges remain, including product quality inconsistency and the need for effective consumer education [16][18][20]. - The dual beauty model is becoming a significant trend, with medical aesthetics companies also venturing into lifestyle beauty, leveraging their technical expertise and clinical data [22][23]. Group 6: Future Outlook - The competition in the medical aesthetics channel is expected to intensify, with beauty brands needing to establish unique advantages through solid technical research and deep medical collaboration [29][30]. - The future winners in this space will be those who can embed "professional trust" in the medical aesthetics channel and leverage "real clinical value" to gain endorsements from both doctors and consumers [30].

Core Insights - The phenomenon of recombinant collagen has ignited enthusiasm in both the market and research sectors, indicating the imminent explosion of the functional protein field, particularly in beauty and skincare [1][2] - The market demand for skin repair products is rapidly increasing, positioning recombinant functional proteins for a golden development period [4][7] Group 1: Market Trends and Consumer Demand - The demand for skin repair products has reached unprecedented levels, with a reported 33.81% year-on-year increase in online discussions about repair products, and 52% of consumers becoming heavy users of sensitive skin repair products [7][9] - The beauty market has entered an era where "everyone needs repair," highlighting the necessity for effective skin repair solutions [9][30] Group 2: Company Innovations and Research - Zhenyan Biotech has developed over 100 self-researched core ingredients for medical device products, focusing on skin barrier repair through synthetic biology [4][6] - The company has established a multi-dimensional recombinant protein repair system, leveraging its decade-long experience to pave a forward-looking path for the functional protein industry [2][13] Group 3: Scientific Foundations and Clinical Validation - Zhenyan Biotech's core philosophy for skin repair is "health first, beauty second," breaking down skin barrier reconstruction into three forces: tolerance, repair, and restoration [11][30] - The company has published nearly 30 academic papers and holds 10 patents related to recombinant mussel adhesive protein, demonstrating its commitment to scientific research and clinical validation [16][19] Group 4: Product Development and Market Position - Zhenyan Biotech has successfully created a product matrix that includes skin disease auxiliary treatment and repair series, addressing diverse consumer needs [25][27] - The company has been recognized as a leader in the Chinese recombinant mussel adhesive protein skincare market, achieving the highest online reputation for three consecutive years [21][30] Group 5: Future Outlook and Strategic Positioning - The development momentum in skin barrier repair and recombinant functional proteins remains strong, with Zhenyan Biotech establishing a robust brand identity centered on "professional repair" [32] - The company's innovative approach in the functional protein sector not only builds a differentiated barrier for its brand but also illuminates a viable path for the high-quality development of the recombinant functional protein industry [32]

Core Viewpoint - Shanghai Jahwa's new CEO Lin Xiaohai is implementing significant reforms to revitalize the company amidst declining performance and increasing competition from international brands and emerging domestic products [1][8]. Group 1: Leadership and Strategy - Lin Xiaohai, with over 25 years of experience at Procter & Gamble, is focusing on brand consolidation and high-end product development [3][4]. - The company is eliminating underperforming sub-brands to concentrate resources on key brands like Six Gods, Baicaoji, and Yuze [4]. - A high-end product line, "Taiji Dan," is being launched under Baicaoji to compete with international brands [4]. Group 2: Operational Changes - The company is optimizing its distribution channels by closing inefficient stores and enhancing online sales, aiming for online revenue to exceed 50% by 2025 [4][10]. - A membership system is being established to improve customer retention and repurchase rates [5]. - The introduction of Procter & Gamble alumni into the management team is expected to enhance operational efficiency [6]. Group 3: Financial Performance - In 2024, Shanghai Jahwa reported a total revenue of 5.679 billion yuan, a year-on-year decline of 13.93%, and a loss of 833 million yuan, a significant drop of 266.60% [8]. - The Q1 2025 report shows a revenue decline of 10% to 1.704 billion yuan, but a profit turnaround to 217 million yuan, indicating a recovery compared to the previous year [10]. Group 4: Future Outlook - The company aims for a revenue target of over 9.5 billion yuan in 2025, with a net profit margin of 8% [15]. - Key brand revenue targets include 2.5 billion yuan for Yuze, 1.8 billion yuan for Baicaoji, and maintaining 3 billion yuan for Six Gods [15]. - The company plans to innovate in both offline and online channels, including the introduction of "smart beauty stores" and doubling GMV on Douyin to 2 billion yuan [15]. Group 5: Market Trends and Challenges - The market for functional skincare is expected to exceed 100 billion yuan by 2026, with "medical research collaboration" becoming a standard in the industry [13]. - International brands maintain a competitive edge in the high-end market, and domestic brands need to establish "technology + culture" barriers [13]. - Rising raw material costs and increasing online customer acquisition costs are significant challenges [13].